Sydney-based biopharma Novogen's (ASX:NRT, Nasdaq:NVGN) US subsidiary, Glycotex, has appointed Dr Reinhard Koenig as CEO and president.

This follows an announcement last week that Glycotex will postpone its IPO on the Nasdaq national market to later in 2006.

Glycotex is a biopharmaceutical company developing drugs for wound healing and tissue repair. Glycotex was originally established as a virtual operation with the company's R&D and clinical trials being conducted by Novogen's staff, based in North Ryde, contracted to Glycotex. The company will now be headquartered in San Francisco.

Koenig, who is also a director of the company, is Glycotex's first appointment, replacing Novogen's managing director Christopher Naughton, who remains as Glycotex's chairman and a director. David Seaton is Glycotex's chief financial officer, director and secretary, Katherine Szem is chair of the audit committee and William Rueckert and Philip Johnston are directors.

Koenig, who officially started work on January 1, has more than 18 years' experience in small and emerging biotech and pharmaceutical companies, as well as in multinational companies, Novogen said.

His most recent position was as vice-president of clinical and product development at US specialty pharma company Questcor Pharmaceuticals. He has also worked for Imcor Pharmaceuticals (formerly known as Photogen Technologies), tissue augmentation product manufacturer Collagen Aesthetics, biotech company Genentech and pharmaceutical company Boehringer Mannheim Therapeutics.